JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Browse 30+ scorpion logo stock videos and clips available to use in your projects, or start a new search to explore more stock footage and b-roll video clips. Zodiac sign Scorpio with white particles ...

Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion. Lilly's long-term potential doesn't hinge on GLP-1 ...

GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion Therapeutics for up to $2.5 billion.